Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
暂无分享,去创建一个
Anne L. Taylor | Clyde W. Yancy | R. D'Agostino | C. Yancy | J. Cohn | K. Adams | K. Ferdinand | P. Carson | S. Ziesche | Susan Ziesche | M. Sabolinski | M. Worcel | Malcolm P. Taylor
[1] 刘金明,et al. IL-13受体α2降低血吸虫病肉芽肿的炎症反应并延长宿主存活时间[英]/Mentink-Kane MM,Cheever AW,Thompson RW,et al//Proc Natl Acad Sci U S A , 2005 .
[2] Tadeusz Malinski,et al. Race-Specific Differences in Endothelial Function: Predisposition of African Americans to Vascular Diseases , 2004, Circulation.
[3] F. Van de Werf,et al. Cardiomyocyte-Specific Overexpression of Nitric Oxide Synthase 3 Improves Left Ventricular Performance and Reduces Compensatory Hypertrophy After Myocardial Infarction , 2004, Circulation research.
[4] S. Prabhu. Nitric oxide protects against pathological ventricular remodeling: reconsideration of the role of NO in the failing heart. , 2004, Circulation research.
[5] J. Stamler,et al. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. , 2004, The Journal of clinical investigation.
[6] Anne L. Taylor. The African-American heart failure trial (A-HeFT): rationale and methodology☆ , 2003 .
[7] C. Yancy. Does race matter in heart failure? , 2003, American heart journal.
[8] G. D. Johnston,et al. Functional Consequences of Endothelial Nitric Oxide Synthase Uncoupling in Congestive Cardiac Failure , 2003, Circulation.
[9] Steven P Jones,et al. Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[10] N. Hollenberg,et al. Literature alert , 2002 .
[11] J. Loscalzo,et al. Effects of Black Race on Forearm Resistance Vessel Function , 2002, Hypertension.
[12] M. Drazner,et al. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. , 2002, Journal of the American College of Cardiology.
[13] L. T. McGrath,et al. Platelet Nitric Oxide and Superoxide Release During the Development of Nitrate Tolerance: Effect of Supplemental Ascorbate , 2002, Circulation.
[14] J. Stamler,et al. Identification of the enzymatic mechanism of nitroglycerin bioactivation , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[15] Anne L. Taylor,et al. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. , 2002, Journal of cardiac failure.
[16] Xiao-Ping Yang,et al. Effect of ACE Inhibitors and Angiotensin II Type 1 Receptor Antagonists on Endothelial NO Synthase Knockout Mice With Heart Failure , 2002, Hypertension.
[17] J. Loscalzo,et al. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. , 2002, Circulation research.
[18] J. Cohn,et al. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.
[19] Richard T. Lee,et al. Endothelial Nitric Oxide Synthase Limits Left Ventricular Remodeling After Myocardial Infarction in Mice , 2001, Circulation.
[20] M. Packer,et al. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. , 2001, Journal of cardiac failure.
[21] D. DeMets,et al. Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.
[22] M. Domanski,et al. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. , 2001, The New England journal of medicine.
[23] M. Domanski,et al. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. , 2001, The New England journal of medicine.
[24] C. Yancy,et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. , 2001, The New England journal of medicine.
[25] D. Harrison,et al. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. , 2000, Circulation research.
[26] C. Yancy. Heart failure in African Americans: A cardiovascular enigma , 2000 .
[27] M. Oz,et al. Nitric oxide modulates mitochondrial respiration in failing human heart. , 1999, Circulation.
[28] Sue-Jane Wang,et al. Modification of Sample Size in Group Sequential Clinical Trials , 1999, Biometrics.
[29] J. Cohn,et al. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. , 1999, Journal of cardiac failure.
[30] D. Harrison,et al. Increased superoxide in heart failure: a biochemical baroreflex gone awry. , 1999, Circulation.
[31] H. Drexler. Nitric oxide synthases in the failing human heart: a doubled-edged sword? , 1999, Circulation.
[32] Fach,et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.
[33] J. Cui,et al. Nonparametric Estimation of a Delay Distribution Based on Left‐Censored and Right‐Truncated Data , 1999, Biometrics.
[34] R. Cannon,et al. Racial differences in nitric oxide-mediated vasodilator response to mental stress in the forearm circulation. , 1998, Hypertension.
[35] A. Omran,et al. Increased oxidative stress in patients with congestive heart failure. , 1998, Journal of the American College of Cardiology.
[36] M. Creager,et al. Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of beta-adrenergic inotropic responsiveness. , 1998, Circulation.
[37] D. Harrison,et al. Cellular and molecular mechanisms of endothelial cell dysfunction. , 1997, The Journal of clinical investigation.
[38] C. Lang,et al. Vasodilation in black Americans: Attenuated nitric oxide‐mediated responses , 1997, Clinical pharmacology and therapeutics.
[39] A. Takeshita,et al. Basal release of nitric oxide is decreased in the coronary circulation in patients with heart failure. , 1997, Hypertension.
[40] V. Smith,et al. Effect of African-American race and hypertensive left ventricular hypertrophy on coronary vascular reactivity and endothelial function. , 1997, Hypertension.
[41] S. Rajagopalan,et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. , 1996, The Journal of clinical investigation.
[42] A. Sherwood,et al. Ethnic differences in forearm vasodilator capacity. , 1996, The American journal of cardiology.
[43] U. Elkayam,et al. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. , 1995, Journal of the American College of Cardiology.
[44] X. Xu,et al. Defective endothelium-mediated control of coronary circulation in conscious dogs after heart failure. , 1994, The American journal of physiology.
[45] J. Cohn,et al. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. , 1992, American heart journal.
[46] E. J. Brown,et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.
[47] D. Hayoz,et al. Endothelial function in chronic congestive heart failure. , 1992, The American journal of cardiology.
[48] T. Rector,et al. Endothelium‐Dependent Vasodilation Is Attenuated in Patients With Heart Failure , 1991, Circulation.
[49] F. Tristani,et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.
[50] J. Bauer,et al. Concurrent Hydralazine Administration Prevents Nitroglycerin‐Induced Hemodynamic Tolerance in Experimental Heart Failure , 1991, Circulation.
[51] J. Belch,et al. Oxygen free radicals and congestive heart failure. , 1991, British heart journal.
[52] F. Tristani,et al. Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. Results of a Veterans Administration Cooperative Study , 1987 .
[53] F. Tristani,et al. Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .
[54] S. Moncada,et al. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor , 1986, Nature.
[55] R. Gillum. Pathophysiology of Hypertension in Blacks and Whites: A Review of the Basis of Racial Blood Pressure Differences , 1979, Hypertension.
[56] E. Bellin. Isosorbide dinitrate and hydralazine in blacks with heart failure. , 2005, The New England journal of medicine.
[57] M. Chandler,et al. Reduced synthesis of NO causes marked alterations in myocardial substrate metabolism in conscious dogs. , 2002, American journal of physiology. Endocrinology and metabolism.
[58] T. R. I. Nvestigators. A TRIAL OF THE BETA-BLOCKER BUCINDOLOL IN PATIENTS WITH ADVANCED CHRONIC HEART FAILURE , 2001 .
[59] P. Mulder,et al. [Oxidative stress and endothelial dysfunction in heart failure]. , 2001, Therapie.
[60] P. Stolley. Racial differences in the outcome of left ventricular dysfunction. , 1999, The New England journal of medicine.
[61] S. García-Castiñeiras,et al. Increased malondialdehyde in peripheral blood of patients with congestive heart failure. , 1996, American heart journal.
[62] David M. Reboussin,et al. Information and information fractions for design and sequential monitoring of clinical trials , 1994 .
[63] K. Swedberg,et al. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.